Head-to-head · WeighScore
SkinnyRx vs Tyde Wellness
By GLP-1 ScorecardUpdated
Score comparison
Tyde Wellness has the higher recorded score — 79.8/100 to 60.5/100.
Tyde Wellness grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tyde Wellness is a 50-state compounded-GLP-1 and longevity telehealth platform spanning weight loss, HRT, hair, and peptides.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | SkinnyRx | Tyde Wellness |
|---|---|---|
| WeighScore | 60.5/100 | 79.8/100 |
| Grade | C | C+ |
| Site position | #284 | #39 |
| Semaglutide | Injection advertised $99 first month; compounded tablets $149 first month. Confirm the recurring price, selected term and usable prescription supply. | $149/mo (microdose tier, all doses, compounded) |
| Tirzepatide | Injection advertised $99 first month; compounded dissolving tablets $199 first month. Confirm the recurring price, selected term and usable prescription supply. | $249/mo (microdose tier, all doses, compounded) |
| Coverage | Current terms exclude certain compounded offerings in Alabama, Louisiana and Mississippi; confirm eligibility for the exact route and pharmacy. | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #284 · C
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Strengths
- Advertises separate first-month prices for both compounded molecules and both injection and tablet routes
- Current terms describe the ninety-day commercial guarantee’s dose logging, claim-window, promotional eligibility and coverage requirements
- Names a medical director/advisor in public information; this does not identify the assigned treating professional
- Publishes compounded-treatment state exclusions and cancellation channels rather than leaving every operational detail unspecified
What to consider
- First-month prices do not establish the recurring amount, selected full prepayment or usable medication quantity
- Cancellation requires five days’ notice before renewal processing, which can itself precede the next subscription period
- The guarantee’s bundled-refund language needs clarification alongside general third-party-fee deductions, medication-return requirements and product FAQ restrictions
- Microdose badges and daily tablet descriptions do not establish a separate price, complete prescription or equivalent branded-treatment results
- The actual prescribing practice, assigned clinician, dispensing pharmacy, physical compounder and patient-lab costs remain unconfirmed
- The named advisor’s Florida record flags discipline and a public complaint, while Oregon lists a surrendered license; neither record determines every clinician’s authority or the patient assignment
- FDA issued Lean Rx Inc. dba SkinnyRx a warning letter on February 20, 2026; website testing claims do not establish independent pharmacy verification.
Site position #39 · C+
Strengths
- All 50 states served (full list published)
- Transparent pricing: semaglutide from $149/mo, tirzepatide from $249/mo
- LegitScript Certified with a verification link
- Five named 503A pharmacy partners with addresses: Belmar (CO), Casa (TX), Olympia (FL), Red Rock (UT), Beaker (TX)
- Free consultation; cancel-anytime subscription with no long-term commitment
What to consider
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- No brand-name GLP-1s (Wegovy, Zepbound, Mounjaro, Ozempic)
- Tirzepatide priced higher than competitors offering $200-$249/mo
- Corporate address and medical director not publicly disclosed
- No NABP.pharmacy seal visible
Featured provider
SkinnyRx
SkinnyRx scores 60.5/100 (C). Publishes four introductory compounded-treatment offers, but continuing costs, usable supply and the interaction between cancellation and refund rules need confirmation.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.